Northern Trust Corp Has $1.44 Billion Stock Position in Boston Scientific Corporation $BSX

Key Points

• Northern Trust Corp reduced its stake in Boston Scientific by 2.0%, now owning approximately 14.3 million shares worth about $1.44 billion.
• Several analysts, including Morgan Stanley and UBS Group, have raised their price targets for Boston Scientific, with a consensus rating of "Buy" and an average price target of $117.50.
• Boston Scientific reported a 22.8% year-over-year increase in revenue, totaling $5.06 billion for the last quarter, exceeding analyst expectations.

Northern Trust Corp reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,302,624 shares of the medical equipment provider's stock after selling 293,003 shares during the quarter. Northern Trust Corp owned 0.97% of Boston Scientific worth $1,442,849,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Brooklyn Investment Group increased its stake in shares of Boston Scientific by 11.7% in the first quarter. Brooklyn Investment Group now owns 12,971 shares of the medical equipment provider's stock valued at $1,309,000 after buying an additional 1,358 shares in the last quarter. Corient IA LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $706,000. Raymond James Financial Inc. increased its stake in shares of Boston Scientific by 1.9% in the first quarter. Raymond James Financial Inc. now owns 2,177,337 shares of the medical equipment provider's stock valued at $219,650,000 after buying an additional 41,422 shares in the last quarter. Boston Family Office LLC increased its stake in shares of Boston Scientific by 32.3% in the first quarter. Boston Family Office LLC now owns 11,499 shares of the medical equipment provider's stock valued at $1,160,000 after buying an additional 2,805 shares in the last quarter. Finally, Ethic Inc. increased its stake in shares of Boston Scientific by 11.1% in the first quarter. Ethic Inc. now owns 268,848 shares of the medical equipment provider's stock valued at $27,218,000 after buying an additional 26,919 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 in the last 90 days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

BSX has been the subject of a number of research reports. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Evercore ISI raised their price target on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Citigroup reiterated a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Stock Up 0.7%

Shares of NYSE:BSX traded up $0.7850 during trading on Friday, hitting $105.9950. 8,236,683 shares of the company's stock traded hands, compared to its average volume of 7,555,358. Boston Scientific Corporation has a 52 week low of $78.53 and a 52 week high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $157.06 billion, a price-to-earnings ratio of 63.09, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66. The company has a 50-day moving average price of $103.97 and a 200-day moving average price of $102.14.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the business posted $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.